Key points are not available for this paper at this time.
Underlines therapeutic gap in HFpEF; leaves open discovery of effective interventions for this prevalent syndrome.
Heart failure (HF) is a major healthcare problem associated with high rates of morbidity and mortality.1 Approximately 6 million Americans aged ≥20 years have HF, and it is the leading cause of hospitalisation among older adults with estimated healthcare costs of US$31 billion annually.1,2 HF with preserved ejection fraction (HFpEF) accounts for over 50 % of all HF cases, and unlike HF with reduced ejection fraction (HFrEF), pharmacological, or device-based therapy do not improve survival or quality of life in patients with HFpEF.3,4
No takes yet. Share an insight, caveat, or question.
Tucker et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: